JP6093707B2 - 化合物製剤 - Google Patents

化合物製剤 Download PDF

Info

Publication number
JP6093707B2
JP6093707B2 JP2013541414A JP2013541414A JP6093707B2 JP 6093707 B2 JP6093707 B2 JP 6093707B2 JP 2013541414 A JP2013541414 A JP 2013541414A JP 2013541414 A JP2013541414 A JP 2013541414A JP 6093707 B2 JP6093707 B2 JP 6093707B2
Authority
JP
Japan
Prior art keywords
mtc
composition
diluent
tablet
compressed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013541414A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544272A5 (enExample
JP2013544272A (ja
Inventor
カーン、カラール、アーマッド
Original Assignee
ウィスタ ラボラトリーズ リミテッド
ウィスタ ラボラトリーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウィスタ ラボラトリーズ リミテッド, ウィスタ ラボラトリーズ リミテッド filed Critical ウィスタ ラボラトリーズ リミテッド
Publication of JP2013544272A publication Critical patent/JP2013544272A/ja
Publication of JP2013544272A5 publication Critical patent/JP2013544272A5/ja
Application granted granted Critical
Publication of JP6093707B2 publication Critical patent/JP6093707B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013541414A 2010-11-30 2011-11-30 化合物製剤 Active JP6093707B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41816410P 2010-11-30 2010-11-30
US61/418,164 2010-11-30
PCT/GB2011/001662 WO2012072977A2 (en) 2010-11-30 2011-11-30 Compound formulations

Publications (3)

Publication Number Publication Date
JP2013544272A JP2013544272A (ja) 2013-12-12
JP2013544272A5 JP2013544272A5 (enExample) 2016-06-16
JP6093707B2 true JP6093707B2 (ja) 2017-03-08

Family

ID=45418703

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013541414A Active JP6093707B2 (ja) 2010-11-30 2011-11-30 化合物製剤

Country Status (10)

Country Link
US (1) US9192611B2 (enExample)
EP (1) EP2645994B1 (enExample)
JP (1) JP6093707B2 (enExample)
CN (1) CN103379901B (enExample)
AU (1) AU2011334679B2 (enExample)
CA (1) CA2818068C (enExample)
ES (1) ES2655492T3 (enExample)
MY (1) MY163074A (enExample)
SG (2) SG10201602111VA (enExample)
WO (1) WO2012072977A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014153444A (ja) * 2013-02-06 2014-08-25 Konica Minolta Inc 位相差フィルム、偏光板及び液晶表示装置
AU2017301966B2 (en) 2016-07-25 2022-09-22 TauRx Therapeutics Management Ltd Administration and dosage of diaminophenothiazines
FR3104438B1 (fr) * 2019-12-12 2021-11-19 Univ Bordeaux Formulation pour le bleu de methylene et procede
EP4531863A1 (en) 2022-05-31 2025-04-09 WisTa Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
EP4590306A1 (en) 2022-09-21 2025-07-30 Yin Sze Loh Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880373A (en) 1988-04-28 1989-11-14 The Upjohn Company Tablet press
JPH0840942A (ja) * 1994-07-29 1996-02-13 Kanegafuchi Chem Ind Co Ltd 薬物放出制御製剤
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
PT1799662E (pt) 2004-09-23 2013-07-09 Wista Lab Ltd Métodos de síntese química e purificação de compostos de diaminofenotiazínio incluindo cloreto de metiltionínio (mtc)
US7790881B2 (en) * 2004-09-23 2010-09-07 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC)
EP2283811A1 (en) * 2004-10-19 2011-02-16 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising donepezil hydrochloride
EP1919456A2 (en) * 2005-08-24 2008-05-14 Wyeth a Corporation of the State of Delaware Bazedoxifene acetate formulations and manufacturing process thereof
EP1808165B1 (en) * 2006-01-05 2009-04-29 Teva Pharmaceutical Industries Ltd Dry formulations of aripiprazole
CN109384741B (zh) 2006-03-29 2023-01-06 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
US20080317678A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
SI2205245T1 (sl) 2007-10-03 2015-10-30 Wista Laboratories Ltd. Terapevtska uporaba diaminofenotiazinov
CN101911081A (zh) 2007-11-05 2010-12-08 维斯塔实验室有限公司 用于临床试验的体系
PL2480540T3 (pl) * 2009-09-24 2018-05-30 Wista Laboratories Ltd. Pentahydrat chlorku metylotioninowego, jego wytwarzanie i zastosowanie farmaceutyczne

Also Published As

Publication number Publication date
MY163074A (en) 2017-08-15
AU2011334679B2 (en) 2016-12-15
ES2655492T3 (es) 2018-02-20
WO2012072977A8 (en) 2012-09-20
SG10201602111VA (en) 2016-04-28
US20130243858A1 (en) 2013-09-19
WO2012072977A2 (en) 2012-06-07
CA2818068A1 (en) 2012-06-07
JP2013544272A (ja) 2013-12-12
CN103379901A (zh) 2013-10-30
CN103379901B (zh) 2018-04-03
EP2645994B1 (en) 2017-11-01
US9192611B2 (en) 2015-11-24
EP2645994A2 (en) 2013-10-09
WO2012072977A3 (en) 2012-08-16
CA2818068C (en) 2019-06-11
AU2011334679A1 (en) 2013-07-18
SG190406A1 (en) 2013-06-28

Similar Documents

Publication Publication Date Title
EP3024442B1 (en) Formulations containing amorphous dapagliflozin
AU2015215000B2 (en) Solid pharmaceutical compositions of androgen receptor antagonists
JP6093707B2 (ja) 化合物製剤
EP2988733B1 (en) Pharmaceutical composition containing crystalline macitentan
EP2068835A2 (en) Imatinib compositions
AU2019232937B2 (en) Ceritinib formulation
JP2013544272A5 (enExample)
JP2008536922A (ja) オランザピンの医薬用経口崩壊錠
KR101823071B1 (ko) 텔미사르탄-함유 정제의 제조방법
JPWO2011081118A1 (ja) 経口投与用医薬組成物
HK1184386B (en) Formulations comprising methylthioninium chloride
HK1184386A (en) Formulations comprising methylthioninium chloride
RU2836778C1 (ru) Фармацевтическая композиция с модифицированным высвобождением на основе полиморфов клозапина
JP7506475B2 (ja) フェブキソスタット製剤
CN106692067B (zh) 双嘧达莫固体分散体、口崩片及其制备方法
TW202435886A (zh) 米爾維仙(milvexian)醫藥組合物
BRPI0621739A2 (pt) formulação estável que consiste em drogas sensìveis à umectação e seu procedimento de fabricação
BR112019020269A2 (pt) formulação farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160112

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160916

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170213

R150 Certificate of patent or registration of utility model

Ref document number: 6093707

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250